IRIS UniCatt

Marchetti, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.044
AS - Asia 4.390
EU - Europa 2.695
SA - Sud America 1.041
Continente sconosciuto - Info sul continente non disponibili 276
AF - Africa 124
OC - Oceania 8
Totale 13.578
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.853
SG - Singapore 2.333
BR - Brasile 863
IT - Italia 679
CN - Cina 635
SE - Svezia 591
VN - Vietnam 386
FR - Francia 307
IE - Irlanda 295
DE - Germania 250
IN - India 205
ID - Indonesia 177
HK - Hong Kong 135
GB - Regno Unito 113
JP - Giappone 104
BD - Bangladesh 102
RU - Federazione Russa 85
FI - Finlandia 83
CA - Canada 82
AR - Argentina 80
MX - Messico 64
CZ - Repubblica Ceca 62
IQ - Iraq 53
NL - Olanda 53
TR - Turchia 39
KR - Corea 34
PK - Pakistan 29
PL - Polonia 28
AT - Austria 26
CO - Colombia 26
VE - Venezuela 24
SA - Arabia Saudita 23
UA - Ucraina 23
ZA - Sudafrica 23
ES - Italia 21
BE - Belgio 19
CH - Svizzera 17
CI - Costa d'Avorio 16
KE - Kenya 15
MA - Marocco 15
TN - Tunisia 15
PH - Filippine 14
AZ - Azerbaigian 13
EC - Ecuador 13
UZ - Uzbekistan 13
EG - Egitto 12
NP - Nepal 11
ET - Etiopia 10
CR - Costa Rica 9
IL - Israele 9
IR - Iran 9
JO - Giordania 9
MY - Malesia 9
PY - Paraguay 9
CL - Cile 8
JM - Giamaica 8
UY - Uruguay 8
BG - Bulgaria 7
KZ - Kazakistan 7
TT - Trinidad e Tobago 7
LT - Lituania 6
OM - Oman 6
PE - Perù 6
AE - Emirati Arabi Uniti 5
AU - Australia 5
DZ - Algeria 5
HN - Honduras 4
HU - Ungheria 4
KG - Kirghizistan 4
KW - Kuwait 4
PT - Portogallo 4
RO - Romania 4
SN - Senegal 4
SY - Repubblica araba siriana 4
AO - Angola 3
GR - Grecia 3
LB - Libano 3
PA - Panama 3
TJ - Tagikistan 3
AL - Albania 2
BB - Barbados 2
BO - Bolivia 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GY - Guiana 2
LV - Lettonia 2
NG - Nigeria 2
PS - Palestinian Territory 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
AM - Armenia 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BZ - Belize 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
Totale 13.282
Salva come PNG Salva come JPEG
Città #
Singapore 1.094
Ashburn 835
San Jose 648
Dublin 291
Chandler 256
Rome 186
Jakarta 167
Los Angeles 165
Beijing 159
Lauterbourg 159
Milan 159
New York 152
Ho Chi Minh City 132
Boston 126
Hong Kong 124
Princeton 116
Hyderabad 103
Hanoi 102
Tokyo 95
Frankfurt am Main 93
Hefei 86
Dallas 74
São Paulo 72
Chicago 65
Santa Clara 62
Munich 61
Washington 59
Buffalo 58
Moscow 57
Helsinki 54
The Dalles 50
Paris 42
Atlanta 40
Brno 38
San Mateo 37
Tukwila 37
Orem 34
Seoul 32
Rio de Janeiro 29
Boardman 27
Kent 27
Seattle 26
Toronto 26
Council Bluffs 24
Da Nang 24
Nuremberg 24
San Francisco 24
Amsterdam 23
London 23
Brooklyn 21
Houston 20
Marseille 20
Naples 20
Shanghai 20
Wilmington 19
Chennai 18
Denver 18
St Louis 18
Warsaw 18
Belo Horizonte 17
Pune 17
Stockholm 17
Vienna 17
Abidjan 16
Baghdad 16
Brussels 16
Ann Arbor 15
Brasília 15
Curitiba 15
Mexico City 15
Phoenix 15
Salt Lake City 15
Bremen 14
Dhaka 14
Montreal 14
Turku 14
Bari 13
Bogotá 13
Campinas 13
Düsseldorf 13
Haiphong 13
Johannesburg 13
Nairobi 13
Poplar 13
Philadelphia 12
Tashkent 12
Baku 11
Brdo 11
Porto Alegre 11
Addis Ababa 10
Hải Dương 10
Lappeenranta 10
Manchester 10
Nanjing 10
Olomouc 10
Praia Grande 10
Salvador 10
Ankara 9
Augusta 9
Charlotte 9
Totale 7.119
Salva come PNG Salva come JPEG
Nome #
Midtrimester isolated short femur and perinatal outcomes: A systematic review and meta-analysis 241
BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study 215
Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer 214
Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial 188
Molecular profile of brca-negative long survivor high grade serous ovarian cancer patients using a somatic multigene panel 171
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments 162
Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance 161
Ovarian reserve after chemotherapy in breast cancer: A systematic review and meta-analysis 159
Vulvo-vaginal reconstruction after radical excision for treatment of vulvar cancer: Evaluation of feasibility and morbidity of different surgical techniques 147
Epithelial ovarian cancer and brain metastases: might the BRCA status, PARP inhibitor administration, and surgical treatment impact the survival? 146
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 137
Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach 137
BRCA testing on buccal swab to improve access to healthcare and cancer prevention: A performance evaluation 136
Ovarian cancer onset across different BRCA mutation types: a view to a more tailored approach for BRCA mutated patients 130
Diet and Chemotherapy: The Effects of Fasting and Ketogenic Diet on Cancer Treatment 130
Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850) 129
Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis 129
BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score 127
Tumor BRCA testing in ovarian cancer and EQA scheme: our experience of a critical evaluation 127
What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study 124
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. 124
Tolerability of bevacizumab in elderly ovarian cancer patients (Turbo study): A case-control study of a real-life experience 123
Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer 120
Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study 119
Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence 119
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery 118
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 117
Fertility preservation in patients with BRCA mutations or Lynch syndrome 115
Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients 111
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 110
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study 110
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study 108
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1 106
Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era—Is it time for a new paradigm shift? A systematic review and meta-analysis 104
High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment 104
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 102
NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer 102
Value of frozen section to tailor surgical staging in apparent early-stage epithelial ovarian cancer 101
Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study 100
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 99
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 98
The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery 95
Letrozole in the management of advanced ovarian cancer: An old drug as a new targeted therapy 94
Pembrolizumab for advanced cervical cancer: safety and efficacy 93
Nomogram to predict feasibility of minimally invasive interval debulking surgery in advanced ovarian cancer 93
Needleoscopic-assisted risk-reducing bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers: Peri-operative outcomes and psychological impact 92
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 92
The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer 87
Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go beyond 86
Bilateral Risk-Reduction Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Meta-analysis 85
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 85
Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status 84
BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study 84
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19) 83
Medical treatment of patients with gynecologic cancer during the COVID-19 pandemic 82
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: A phase II, open label multicenter study (NUVOLA trial) 82
Vaginectomy: a minimally invasive treatment for cervical cancer vaginal recurrence 82
Targeted drug delivery via folate receptors in recurrent ovarian cancer: A review 81
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 81
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 79
A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: A multicentric Italian experience 78
Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients 77
Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes 77
A commentary on the discrepancy between blood and tumour BRCA testing: An open question 77
Immune check-point in cervical cancer 77
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies 76
Beyond the beyond: First case of 9 cytoreductive surgeries in a long-surviving ovarian cancer patient: Case report 75
Fertility preservation in gynaecologic cancers 72
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 72
The Role of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis 71
Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis 71
The INCH trial - Induction chemotherapy in patients with bulky anal canal cancer: Evaluation of the pilot phase 69
Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study 67
Ixabepilone for the treatment of endometrial cancer 67
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors 67
Dualistic classification of epithelial ovarian cancer: Surgical and survival outcomes in a large retrospective series 67
Detecting Large Germline Rearrangements of BRCA1 by Next Generation Tumor Sequencing 66
Radiation effects on male fertility 66
Origin of residual tumor masses in {BRCA}1/2-driven ovarian carcinomas treated by neoadjuvant chemotherapy: selection of preexisting {BRCA}1/2-proficient tumor cells but not the gain of second {ORF}-restoring mutation 65
Nonabsorbable suture granuloma mimicking ovarian cancer recurrence at combined positron emission tomography/computed tomography evaluation: A case report 65
Bartholin gland cancer 64
Reactive lymphoid hyperplasia of liver mimicking late ovarian cancer recurrence: Case report and literature review 64
Update on fertility-sparing treatment in primary and recurrent endometrial cancer 64
Threatened abortion and late-pregnancy complications: A case-control study and review of literature 64
Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations 63
Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors 63
Combined Plasma Fibrinogen and Neutrophil Lymphocyte Ratio in Ovarian Cancer Prognosis May Play a Role? 63
Secondary cytoreductive surgery: Surgical approach to bulky aortic nodes, splenic metastases and mesenteric disease 63
Cediranib in ovarian cancer: state of the art and future perspectives 63
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression 63
Olfactomedin-4 regulation by estrogen in the human endometrium requires epidermal growth factor signaling 62
Response to: Should we or should we not? Risk reduction bilateral salpingectomy for BRCA mutation carriers 62
Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review 62
A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer 61
First-line treatment of women with advanced ovarian cancer: Focus on bevacizumab 60
Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: The role of erythropoietic growth factors 59
Weekly versus three weeks chemotherapy for advanced ovarian cancer: A meta-analysis 59
Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer 59
Vulvodynia: Current opinion and treatment strategies 59
Immune check-point in endometrial cancer 59
Totale 9.718
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.697
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.697
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022463 0 3 3 23 5 8 14 46 11 27 146 177
2022/20231.358 200 190 113 97 84 192 90 93 148 37 73 41
2023/20241.582 35 337 77 203 87 258 134 43 24 66 172 146
2024/20252.634 61 53 223 74 149 91 74 83 483 328 540 475
2025/20266.484 1.089 154 368 659 1.000 358 1.145 312 401 421 279 298
2026/2027885 470 415 0 0 0 0 0 0 0 0 0 0
Totale 13.578